Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy

Current Opinion in Oncology

Volumn 24, Issue 3, 2012, Pages 211-217

  De Andrade, Diocésio A P ^a   Machiels, Jean Pascal ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

chemotherapy; platinum pretreated; squamous cell carcinoma; targeted therapies

Indexed keywords

3' ETHYNYLCYTIDINE; AFATINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; LINSITINIB; METFORMIN; METHOTREXATE; NAVELBINE; PACLITAXEL; PANITUMUMAB; PAZOPANIB; ZALUTUMUMAB;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE COURSE; DRUG ACTIVITY; DRUG HYPERSENSITIVITY; HEAD AND NECK CANCER; HUMAN; METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; PLATINUM COMPOUNDS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84859842130     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283510773     Document Type: Review

References (54)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2008; 58:71-96.
2. Raggin CC, Modugno F, Gollin SM. The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 2007; 86:104-114.
3. Blot WJ, McLaughlin JK, Winn DM, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 48:3282-3287.
4. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006; 24:2606-2611. (Pubitemid 46622080)
5. Kowalski LP, Carvalho AL. Natural history of untreated head and neck cancer. Eur J Cancer 2000; 36:1032-1037. (Pubitemid 30316429)
6. Cohen EEW, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004; 22:1743-1752. (Pubitemid 41079815)
7. Garden AS, Asper JA, Morrison WH, et al. Is concurrent chemoradiation the treatment of choice for all patients with stage III or IV head and neck carcinoma? Cancer 2004; 100:1171-1178. (Pubitemid 38325944)
8. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993; 328:184-194.
9. Browman GP, Cronin L. Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials. Semin Oncol 1994; 21:311-319. (Pubitemid 24191590)
10. Gibson MK, Li Y, Murphy B, et al., Eastern Cooperative Oncology Group. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 15:3562-3567.
11. Vermorken J, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Eng J Med 2008; 11:1116-1127.
12. Vermorken J, Stohlmacher J, Davidenko I, et al. Primary efficacy and safety results of SPECTRUM, a phase 3 trial in patients (pts) with recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) receiving chemotherapy with or without panitumumab (PMAB). Ann Oncol 2010; 21 (S8):viii12.
13. Machiels JP, Schmitz S. Management and palliative chemotherapy for metastatic or recurrent squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther 2011; 11:359-371.
14. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10:257-263.
15. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: a phase-III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994; 5:521-526. (Pubitemid 24223504)
16. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10:1245-1251.
17. Stewart JSW, Cohen EEW, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27:1864-1871.
18. Baselga J, Trigo JM, Tortochaux J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinumrefractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5568-5577.
19. Machiels JP, Subramanian S, Ruzsa A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomized phase 3 trial. Lancet Oncol 2011; 12:333-343. The only phase 3 trial investigating an anti-EGFR MoAb after platinum failure.
20. Leon X, Hitt R, Constenla M, et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol(R Coll Radiol) 2005; 17:418-424. (Pubitemid 41136136)
21. Vermorken JB, Herbst RS, Leon X, et al. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 2008; 112:2710-2719. (Pubitemid 351969215)
22. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5578-5587.
23. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25:2171-2177. (Pubitemid 46954639)
24. Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomized phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004; 40:2071-2076. (Pubitemid 39165540)
25. Vermorken J, Catimel G, Mulder PD, et al. Randomized phase II trial of weekly methotrexate (MTX) versus two schedules of triweekly paclitaxel (Taxol [trade]) in patients with metastatic or recurrent squamous cell carcinomaof the head and neck (SCCHN) [abstract]. Proc Am Soc Clin Oncol 1999; 17:1527.
26. Schrijvers D, Vermorken JB. Taxanes in the treatment of head and neck cancer. Curr Opin Oncol 2005; 17:218-224. (Pubitemid 40586160)
27. Forastiere AA, Shank D, Neuberg D, et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998; 82:2270-2274. (Pubitemid 28240836)
28. Langer CJ, Li Y, Jennings T, et al. Phase II evaluation of 96-h paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group. Cancer Invest 2004; 22:823-831. (Pubitemid 39665346)
29. Grau JJ, Caballero M, Verger E, et al. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol 2009; 129:1294-1299.
30. Fayette J, Montella A, Chabaud S, et al. Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution. Anticancer Drugs 2010; 21:553-558.
31. Tahara M, Minami H, Hasegawa Y, et al. Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer. Cancer Chemother Pharmacol 2011; 68:769-776.
32. Numico G, Merlano M. Second-line treatment with docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer. Ann Oncol 2002; 13:331-333. (Pubitemid 34704989)
33. Cho BC, Keum KC, Shin SJ, et al. Weekly docetaxel in patients with platinumrefractory metastatic or recurrent squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 2009; 65:27-32.
34. Specenier P, Rasschaert M, Vroman P, et al. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Am J Clin Oncol 2011; 34:472-477.
35. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24:2644-2652. (Pubitemid 46628471)
36. Argiris A, Karamouzis MV, Gooding WE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 2011; 29:1140-1145.
37. Pfister DG, Haque S, Stambuk H, et al. A phase II study of pemetrexed (P) plus gemcitabine (G) in patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC) [abstract]. J Clin Oncol 2010; 28 (Suppl): 5554.
38. Shirai K, Saddoughi S, O'Brien PE, et al. Serum C18-ceramide as a biomarker for response: phase II trial of gemcitabine plus doxorubicin in patients with HNSCC [abstract]. J Clin Oncol 2010; 29 (Suppl):5590.
39. Yarden Y. The EGFR family and its ligands in human cancer, signaling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37:S3-S8. (Pubitemid 32938123)
40. Temam S, Kawaguchi H, El-Naggar Ak, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007; 25:2164-2170. (Pubitemid 46954638)
41. Zakaria H, Jordan WO, Wildfang I, et al. Cetuximab in combination with bendamustine as an alternative therapeutic option for recurrent head and neck cancer [abstract 1034 P]. Ann Oncol 2010; 21 (Suppl 8):viii322.
42. Ceruse P, Lavergne E, Buiret G, et al. Paclitaxel (TLX) and cetuximab (CTX) combination efficiency after failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma (RMHNSCC) [abstract]. J Clin Oncol 2011; 29 (Suppl):5549.
43. Jimenez B, Perez JMT, Medina MIS, et al. Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients [abstract]. J Clin Oncol 2011; 29 (Suppl):5594.
44. Rozzi A, Lenci G, Corona M, et al. Weekly regimen of paclitaxel- carboplatincetuximab as first-line chemotherapy in patients with platinum-resistant recurrent or metastatic squamous cell carcinoma of head and neck (SSCHN): results of a phase II study [abstract 1035 P]. Ann Oncol 2010; 21 (Suppl 8): viii323.
45. Cohen E. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24:2659-2665. (Pubitemid 46622087)
46. Argiris A, Ghebremichael M, Gilbert J, et al. A phase III randomized, placebocontrolled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): a trial of the Eastern Cooperative Oncology Group (ECOG)[abstract]. J Clin Oncol 2009; 27(suppl):6011.
47. Seiwert TY, Clement PM, Cupissol D, et al. BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: preliminary results of a randomized, open-label phase II study [abstract]. J Clin Oncol 2010; 28 (Suppl):5501.
48. Seiwert TY, Fayette J, Del Campo JM, et al. Updated results of a randomized, open-label phase II study exploring BIBW 2992 versus cetuximab in patients with platinum-refractory metastatic/recurrent head and neck cancer (SCCHN) [abstract 1010 PD]. Ann Oncol 2010; 21 (Suppl 8):viii316.
49. Lai SY, Koppikar P, Thomas SM, et al. Intratumoral growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanism. J Clin Oncol 2009; 27:1235-1242.
50. Schmitz S, Kaminsky-Forrett MC, Henry S, et al. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: GORTEC 2008-02. Ann Oncol 2012; doi:10.1093/annonc/ mdr574.
51. Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck. Lancet Oncol 2009; 10:247-257.
52. Williamson SK, Moon J, Huang CH, et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0420. J Clin Oncol 2010; 28:3330-3335.
53. Sabichi AL, Kies MS, Glisson BS, et al. A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN) [abstract]. J Clin Oncol 2010; 28 (Suppl):5532.
54. Machiels JPH, Henry S, Zanetta S, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010; 28:21-28.